{"contentid": 488015, "importid": NaN, "name": "COVID-19 Vaccine Janssen becomes 4th backed for authorization by EMA", "introduction": "Marking the fourth vaccine to be recommended for the prevention of the novel coronavirus by the European Medicines Agency, the EMA today revealed it has recommended granting a conditional marketing authorization for COVID-19 Vaccine Janssen in people from 18 years of age.", "content": "<p>Marking the fourth vaccine to be recommended for the prevention of the novel coronavirus by the European Medicines Agency, the EMA today revealed it has recommended granting a conditional marketing authorization for COVID-19 Vaccine Janssen in people from 18 years of age.</p>\n<p>After a thorough evaluation, the EMA&rsquo;s human medicines committee, CHMP, concluded by consensus that the data on the vaccine were robust and met the criteria for efficacy, safety and quality.</p>\n<p>Johnson &amp; Johnson (NYSE: JNJ) subsidiary Janssen&rsquo;s vaccine thus joins Pfizer (NYSE: PFE)/BioNTech (Nasdaq: BNTX), AstraZeneca (LSE: AZN)/Oxford and Moderna (Nasdaq: RMNA) in gaining approval for their covid jabs, with this coming on the first anniversary of the World Health Organization declaring the pandemic on March 11, 2020.</p>\n<p>&ldquo;With this latest positive opinion, authorities across the European Union will have another option to combat the pandemic and protect the lives and health of their citizens,&rdquo; said Emer Cooke, the EMA&rsquo;s executive director, adding, &ldquo;this is the first vaccine which can be used as a single dose.&rdquo;</p>\n<p>In a statement from J&amp;J this afternoon that also noted the EMA recommendation had been confirmed by the European Commission, the company said it is committed to making its COVID-19 vaccine available on a not-for profit basis for emergency pandemic use. The company aims to begin delivery of its single-dose COVID-19 vaccine to the EU in the second half of April and to supply 200 million doses to the EU, plus Norway and Iceland in 2021.</p>\n<h2><strong>Clinical backing</strong></h2>\n<p>Results from a clinical trial involving people in the USA, South Africa and Latin American countries found that COVID-19 Vaccine Janssen was effective at preventing COVID-19 in people from 18 years of age. This study involved over 44,000 people. Half received a single dose of the vaccine and half were given placebo.</p>\n<p>The trial found a 67% reduction in the number of symptomatic COVID-19 cases after two weeks in people who received COVID-19 Vaccine Janssen (116 cases out of 19,630 people) compared with people given placebo (348 of 19,691 people). This means that the vaccine had a 67% efficacy.</p>\n<p>The side effects with COVID-19 Vaccine Janssen in the study were usually mild or moderate and cleared within a couple of days after vaccination. The most common ones were pain at the injection site, headache, tiredness, muscle pain and nausea.</p>\n<p>The safety and effectiveness of the vaccine will continue to be monitored as it is used across the EU, through the EU pharmacovigilance system and additional studies by the company and European authorities.</p>", "date": "2021-03-11 16:41:00", "meta_title": "COVID-19 Vaccine Janssen becomes 4th backed for authorization by EMA", "meta_keywords": "COVID-19 Vaccine Janssen, Conditional,  Authorization,  EMA, Johnson & Johnson", "meta_description": "COVID-19 Vaccine Janssen becomes 4th backed for authorization by EMA", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-11 16:40:15", "updated": "2021-03-11 17:07:25", "access": NaN, "url": "https://www.thepharmaletter.com/article/covid-19-vaccine-janssen-becomes-4th-backed-for-authorization-by-ema", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "janssen_johnson_big.jpg", "image2id": "janssen_johnson_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "COVID-19 vaccines", "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, European Medicines Agency, Focus On, Regulation", "geography_tag": "Europe, USA", "company_tag": "Janssen, Johnson & Johnson", "drug_tag": "COVID-19 Vaccine Janssen", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-11 16:41:00"}